Home > Gastroenterology > ECCO 2022 > Head-to-Head Comparisons > Subcutaneous infliximab versus subcutaneous vedolizumab in IBD

Subcutaneous infliximab versus subcutaneous vedolizumab in IBD

Presented By
Prof. Laurent Peyrin-Biroulet, Nancy University Hospital, France

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
Subcutaneous infliximab therapy outperformed subcutaneous vedolizumab therapy in participants with Crohn’s disease (CD), according to a comparative analysis. In participants with ulcerative colitis (UC), the 2 therapies appeared to be equally efficacious. The safety profiles of subcutaneous infliximab and vedolizumab therapies were comparable over 1 year of follow-up in both CD and UC. Prof. Laurent Peyrin-Biroulet (Nancy University Hospital, France) compared the efficacy of subcutaneous infliximab and subcutaneous vedolizumab induction and maintenance therapies in participants with CD and UC, using data from 7 randomised-controlled trials [1]. The infliximab subcutaneous trial (NCT02883452) was compared with trials on vedolizumab including GEMINI II, GEMINI III, and VISIBLE 2 for CD and GEMINI I, VISIBLE 1, and VARSITY for UC. In participants with...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on